tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

INDP Stock Latest News

Indaptus Therapeutics Elects Directors and Approves Key Proposals
Company AnnouncementsIndaptus Therapeutics Elects Directors and Approves Key Proposals
1M ago
8K
INDP
Indaptus Therapeutics announces updated data from Phase 1 Decoy20 trial
PremiumThe Fly
Indaptus Therapeutics announces updated data from Phase 1 Decoy20 trial
2M ago
INDP
Indaptus Therapeutics to present new cohort data on Phase 1 trial of Decoy20
PremiumThe Fly
Indaptus Therapeutics to present new cohort data on Phase 1 trial of Decoy20
2M ago
INDP
Indaptus announces successful advancement of Phase 1 trial for Decoy20
PremiumThe Fly
Indaptus announces successful advancement of Phase 1 trial for Decoy20
2M ago
INDP
Indaptus Therapeutics reports Q1 EPS (45c) vs (51c) last year
PremiumThe Fly
Indaptus Therapeutics reports Q1 EPS (45c) vs (51c) last year
2M ago
INDP
Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting
PremiumPress ReleasesIndaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting
3M ago
INDP
Indaptus presents mechanism of action data at AACR for Decoy platform
PremiumThe Fly
Indaptus presents mechanism of action data at AACR for Decoy platform
3M ago
INDP
Indaptus Therapeutics previews presentation of mechanism of action data
PremiumThe Fly
Indaptus Therapeutics previews presentation of mechanism of action data
4M ago
INDP
Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting
PremiumPress Releases
Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting
4M ago
INDP
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
PremiumPress Releases
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
4M ago
INDP
Indaptus Therapeutics expects cash to support activities through 3Q24
PremiumThe Fly
Indaptus Therapeutics expects cash to support activities through 3Q24
4M ago
INDP
Indaptus Therapeutics reports 2023 EPS ($1.83) vs. ($1.73) last year
PremiumThe Fly
Indaptus Therapeutics reports 2023 EPS ($1.83) vs. ($1.73) last year
4M ago
INDP
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
PremiumPress ReleasesIndaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
5M ago
INDP
Indaptus announces results from second cohort in Phase 1 INDP-D101 trial
PremiumThe Fly
Indaptus announces results from second cohort in Phase 1 INDP-D101 trial
5M ago
INDP
Indaptus Therapeutics launches new social media initiative to provide education
PremiumThe Fly
Indaptus Therapeutics launches new social media initiative to provide education
5M ago
INDP
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels
PremiumPress Releases
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels
5M ago
INDP
Indaptus Therapeutics to receive European patent for platform technology
PremiumThe Fly
Indaptus Therapeutics to receive European patent for platform technology
7M ago
INDP
European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology
PremiumPress Releases
European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology
7M ago
INDP
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
PremiumPress Releases
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
9M ago
INDP
Indaptus Therapeutics announces interim data from Phase 1 INDP-D101 trial
PremiumThe FlyIndaptus Therapeutics announces interim data from Phase 1 INDP-D101 trial
9M ago
INDP
Indaptus to present interim data of first cohort in trial of INDP-D101
PremiumThe Fly
Indaptus to present interim data of first cohort in trial of INDP-D101
9M ago
INDP
Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting
PremiumPress Releases
Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting
9M ago
INDP

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >